Endogenous expression of PD-L1 in EML4-ALK positive NSCLC was attenuated by treatment with ALK inhibitor alectinib as well as inhibitors of downstream pathways (MEK-ERK and PI3K-AKT) [29]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.